Merck (NYSE: MRK) reported Q2 EPS of $2.28, $0.12 better than the analyst estimate of $2.16. Revenue for the quarter came in at $16.11 billion versus the consensus estimate of $15.85 billion.

GUIDANCE:

Merck sees FY2024 EPS of $7.94-$8.04, versus the consensus of $8.16. Merck sees FY2024 revenue of $63.4-64.4 billion, versus the consensus of $64.3 billion.

For earnings history and earnings-related data on Merck (MRK) click here.